Literature DB >> 17588254

The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation.

Damian G Downey1, Simon Brockbank, S Lorraine Martin, Madeleine Ennis, J Stuart Elborn.   

Abstract

BACKGROUND: Chronic infection in cystic fibrosis (CF) and airway inflammation leads to progressive lung injury. Neutrophils are considered to be responsible for the onset and promotion of the inflammatory response within the CF lung. The relationship between infection and inflammation is complex but circulating inflammatory markers may not truly reflect the local inflammatory response in the lung. The aims of this study were to investigate the change of inflammatory biomarkers and cells within sputum and blood before and after intravenous antibiotics for a pulmonary exacerbation of CF.
METHODS: Assays included neutrophil elastase (NE) and complex, interleukin-8 (IL-8) and soluble intercellular adhesion molecule-1 (sICAM-1), fas ligand (FAS-L), and TNFr-1. Analysis of sputum cell differential and absolute cell counts and immunocytochemistry (CD11b and CD95) on sputum and isolated blood neutrophils were carried out.
RESULTS: There were no significant differences in absolute or differential sputum cell counts or sputum sol measurements following antibiotics. There was a significant increase in the percentage of blood neutrophils with minimal CD11b staining, 28 (4.1) mean percentage (SEM) versus 41 (2.9) and a decrease in the percentage showing maximal staining 30 (0.5) versus 15 (2.5). There was a significant increase in the percentage of blood neutrophils without CD95 staining, 43 (5.4) mean percentage versus 52 (5.1).
CONCLUSION: These data suggest a modifiable systemic response to i.v. antibiotics but a local sustained inflammatory response in the lung. 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17588254     DOI: 10.1002/ppul.20646

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  14 in total

Review 1.  Proteases, cystic fibrosis and the epithelial sodium channel (ENaC).

Authors:  P H Thibodeau; M B Butterworth
Journal:  Cell Tissue Res       Date:  2012-05-22       Impact factor: 5.249

2.  Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis.

Authors:  Theresa A Laguna; Brandie D Wagner; Heidi K Luckey; Shelley A Mann; Scott D Sagel; Warren Regelmann; Frank J Accurso
Journal:  Chest       Date:  2009-06-30       Impact factor: 9.410

3.  Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation.

Authors:  Theresa A Laguna; Brandie D Wagner; Barry Starcher; Heidi K Luckey Tarro; Shelley A Mann; Scott D Sagel; Frank J Accurso
Journal:  Pediatr Pulmonol       Date:  2012-03-19

Review 4.  Biomarkers for cystic fibrosis drug development.

Authors:  Marianne S Muhlebach; J P Clancy; Sonya L Heltshe; Assem Ziady; Tom Kelley; Frank Accurso; Joseph Pilewski; Nicole Mayer-Hamblett; Elizabeth Joseloff; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2016-10-27       Impact factor: 5.482

5.  Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.

Authors:  Scott D Sagel; Valeria Thompson; James F Chmiel; Gregory S Montgomery; Samya Z Nasr; Elizabeth Perkett; Milene T Saavedra; Bonnie Slovis; Margaret M Anthony; Peggy Emmett; Sonya L Heltshe
Journal:  Ann Am Thorac Soc       Date:  2015-05

6.  Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung disease.

Authors:  Milene T Saavedra; Grant J Hughes; Linda A Sanders; Michelle Carr; David M Rodman; Christopher D Coldren; Mark W Geraci; Scott D Sagel; Frank J Accurso; James West; Jerry A Nick
Journal:  Am J Respir Crit Care Med       Date:  2008-08-21       Impact factor: 21.405

7.  Glucose tolerance during pulmonary exacerbations in children with cystic fibrosis.

Authors:  John Widger; Mark R Oliver; Michele O'Connell; Fergus J Cameron; Sarath Ranganathan; Phil J Robinson
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

Review 8.  Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults.

Authors:  Khin Hnin; Chau Nguyen; Kristin V Carson; David J Evans; Michael Greenstone; Brian J Smith
Journal:  Cochrane Database Syst Rev       Date:  2015-08-13

9.  Potential of anti-inflammatory treatment for cystic fibrosis lung disease.

Authors:  Jennifer L Taylor-Cousar; Kelsey A Von Kessel; Robert Young; David P Nichols
Journal:  J Inflamm Res       Date:  2010-08-10

10.  Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients.

Authors:  Gabriella Wojewodka; Juan B De Sanctis; Joanie Bernier; Julie Bérubé; Heather G Ahlgren; Jim Gruber; Jennifer Landry; Larry C Lands; Dao Nguyen; Simon Rousseau; Andrea Benedetti; Elias Matouk; Danuta Radzioch
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.